Sustiva shows sustained success
A study suggests that there may be an improvement with the long-term success in HIV-positive patients who switch from a protease inhibitor-containing regimen to a regimen containing Sustiva.
The study, which was presented at the first International AIDS Society conference on HIV treatment, indicates that patients who substituted DuPont Pharmaceuticals' anti-HIV drug Sustiva, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for a PI in a suppressive PI-containing course of treatment maintained their viral load suppression for longer than patients who kept to their PI-containing treatment.
The results provide an option for patients who want to remove PIs from their treatment while maintaining virologic control.